Predict your next investment

Corporation
HEALTHCARE | Biotechnology
axxam.com

See what CB Insights has to offer

Investments

1

Partners & Customers

10

About Axxam SpA

Axxam is a science-driven biotechnology company, which offers early-stage discovery research services for the life science industry.nThe company apply the company's from genes to leads activities to Discovery Services that the company provide for the company's customers and to internal Discovery Research.

Axxam SpA Headquarter Location

San Raffaele Biomedical Science Park via Olgettina 58

20132,

Italy

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Axxam SpA Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Axxam SpA Rank

Latest Axxam SpA News

Hypoxia Market Has Exploded: Opportunities & Challenges in Near Future with Key Players like CASI Pharmaceuticals Inc, Spotlight Labs,LLC, F.Hoffmann-La Roche Ltd, AXXAM S.p.A.

Feb 18, 2021

. Hypoxia market is a condition in which the body does not get enough oxygen for supply and oxygen therapy is provided in the complete absence of oxygen, so that the tissue can get oxygen in sufficient manner. It is diagnosed by physical examination and by using oxygen monitors, which are also known as pulse oximeters. It is used in various applications such as in hospitals, specialty clinics. Hypoxia market estimated to register substantial CAGR in the forecast period of 2019 to 2026. The report contains data for historic year 2017 and the base year of calculation is 2018. The growth of the market can be attributed to the strategic initiatives by the market players. This Hypoxia Market research report intensely analyses the potential of the market with respect to current scenario and the future prospects by considering several industry aspects of Cardinal Health industry. The report also recognizes and analyses the rising trends along with major drivers, challenges and opportunities in the market. This Hypoxia Market report provides major statistics on the market status of global and regional manufacturers and is a helpful source of assistance and direction for companies and individuals interested in Healthcare industry. The company profiles of all the chief and dominating market players and brands who are taking steps such as product launches, joint ventures, mergers and acquisitions are mentioned in the report. To Get This Report at 30% Discount, Click Here Growing investment in R&D expenditure is boosting the market in the forecast period Rising prevalence of hypoxic condition will propel the growth of the market Technological advancement is also fueling the market growth Availability of substitute in the market is hampering the market growth Strict government regulation will also restraint the market in the forecast period Availability of nutrients and eating fish can reduce hypoxia which may hinder the market growth The major players covered in the Hypoxia Market Some of the major companies functioning in global hypoxia market are Aileron Therapeutics, Inc., CASI Pharmaceuticals Inc, Spotlight Labs,LLC, F.Hoffmann-La Roche Ltd, AXXAM S.p.A, HypOxygen, Oncolmmune, Nasdaq,Inc, Hancock Medical Inc, Phio Pharmaceuticals, International Marketers For Scientific Equipments & Technologies, Coy Laboratory Products, Inc, Thermo Fisher Scientific, Baker, STEMCELL Technologies Inc, Bioxia, Hypxico Europe, Merck KGaA among others. Major TOC Of The Report Chapter One: Hypoxia Market Overview Chapter Two: Manufacturers Profiles Chapter Four: Global Hypoxia Market Size by Regions Chapter Five: North America Hypoxia Market Revenue by Countries Chapter Six: Europe Hypoxia Market Revenue by Countries Chapter Seven: Asia-Pacific Hypoxia Market Revenue by Countries Chapter Eight: South America Hypoxia Market Revenue by Countries Find More Competitor in TOC with Profile Overview Share Growth Analysis @

Axxam SpA Investments

1 Investments

Axxam SpA has made 1 investments. Their latest investment was in Acousia Therapeutics as part of their Series A on December 12, 2016.

CBI Logo

Axxam SpA Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/15/2016

Series A

Acousia Therapeutics

$2.6M

Yes

2

Date

12/15/2016

Round

Series A

Company

Acousia Therapeutics

Amount

$2.6M

New?

Yes

Co-Investors

Sources

2

Axxam SpA Partners & Customers

10 Partners and customers

Axxam SpA has 10 strategic partners and customers. Axxam SpA recently partnered with ERS Genomics on April 4, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

4/2/2020

Licensor

ERS Genomics

Ireland

ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services

DUBLIN & MILAN -- -- ERS Genomics Limited , which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier , and Axxam S.p.A. , a leading discovery biology company , today announced the signing of a license agreement granting Axxam S.p.A. access to ERS Genomics Limited ' CRISPR-Cas9 patent portfolio , to support Axxam S.p.A. 's integrated discovery service platform .

2

1/14/2020

Partner

Zobio

Netherlands

ZoBio - Drug Discovery Technology Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms.

Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads .

1

8/1/2017

Partner

Enamine

United States

Axxam enters into a Research Collaboration with Enamine for the enhancement of the Axxam Screening Collection - AXXAM

August 1st , 2017 -- Milan and Kiev -- Axxam S.p.A. and Enamine Ltd. today announced the start of a Research Collaboration to enhance the Axxam S.p.A. small molecule screening library with the addition of a further set of compounds aimed at early-stage CNS drug discovery , achieving a total library size of ca. 280,000 compounds .

1

2/1/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

3/3/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

4/2/2020

1/14/2020

8/1/2017

2/1/2017

3/3/2016

Type

Licensor

Partner

Partner

Partner

Partner

Business Partner

ERS Genomics

Zobio

Enamine

Country

Ireland

Netherlands

United States

Subscribe to see more

Subscribe to see more

News Snippet

ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services

DUBLIN & MILAN -- -- ERS Genomics Limited , which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier , and Axxam S.p.A. , a leading discovery biology company , today announced the signing of a license agreement granting Axxam S.p.A. access to ERS Genomics Limited ' CRISPR-Cas9 patent portfolio , to support Axxam S.p.A. 's integrated discovery service platform .

ZoBio - Drug Discovery Technology Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms.

Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads .

Axxam enters into a Research Collaboration with Enamine for the enhancement of the Axxam Screening Collection - AXXAM

August 1st , 2017 -- Milan and Kiev -- Axxam S.p.A. and Enamine Ltd. today announced the start of a Research Collaboration to enhance the Axxam S.p.A. small molecule screening library with the addition of a further set of compounds aimed at early-stage CNS drug discovery , achieving a total library size of ca. 280,000 compounds .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Axxam SpA Team

3 Team Members

Axxam SpA has 3 team members, including current Chief Executive Officer, Stefan Lohmer.

Name

Work History

Title

Status

Stefan Lohmer

Bayer HealthCare

Chief Executive Officer

Current

Alessandro Sidoli

Italian Angels for Biotech

Chief Executive Officer

Current

Luigi Gavazzeni

Chief Financial Officer

Former

Name

Stefan Lohmer

Alessandro Sidoli

Luigi Gavazzeni

Work History

Bayer HealthCare

Italian Angels for Biotech

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.